Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shoko Matsui

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Anticancer Research|December 8, 2019
Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint InhibitorMinehiko Inomata, Tomonobu Kado, Seisuke Okazawa, et al.
Molecular and Clinical Oncology|April 29, 2016
Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinibMinehiko Inomata, Ryuji Hayashi, Hiroaki Tanaka, et al.
Cancer Diagnosis & Prognosis|May 9, 2022
Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung CancerMinehiko Inomata, Masahiro Matsumoto, Isami Mizushima, et al.
Modern Rheumatology|January 7, 2020
Hypocomplementemia is related to elevated serum levels of IgG subclasses other than IgG4 in IgG4-related kidney diseaseYuhei Fujisawa, Ichiro Mizushima, Kazunori Yamada, et al.
Anticancer Research|June 23, 2023
Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint InhibitorsMinehiko Inomata, Masahiro Matsumoto, Kana Hayashi, et al.
Molecular and Clinical Oncology|July 15, 2015
Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinibMinehiko Inomata, Ryuji Hayashi, Azusa Yamamoto, et al.
Scientific Reports|July 4, 2023
Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancerMinehiko Inomata, Masahiro Matsumoto, Naoki Takata, et al.
Arthritis Research & Therapy|November 26, 2016
Factors related to renal cortical atrophy development after glucocorticoid therapy in IgG4-related kidney disease: a retrospective multicenter studyIchiro Mizushima, Motohisa Yamamoto, Dai Inoue, et al.
Endocrine Journal|May 20, 2015
Association of serum adiponectin with asthma and pulmonary function in the Japanese populationYasuko Hayashikawa, Minoru Iwata, Minehiko Inomata, et al.
Molecular and Clinical Oncology|May 17, 2024
Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expressionMinehiko Inomata, Shuhei Minatoyama, Naoki Takata, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Anticancer Research|December 8, 2019
Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint InhibitorMinehiko Inomata, Tomonobu Kado, Seisuke Okazawa, et al.
Molecular and Clinical Oncology|April 29, 2016
Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinibMinehiko Inomata, Ryuji Hayashi, Hiroaki Tanaka, et al.
Cancer Diagnosis & Prognosis|May 9, 2022
Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung CancerMinehiko Inomata, Masahiro Matsumoto, Isami Mizushima, et al.
Modern Rheumatology|January 7, 2020
Hypocomplementemia is related to elevated serum levels of IgG subclasses other than IgG4 in IgG4-related kidney diseaseYuhei Fujisawa, Ichiro Mizushima, Kazunori Yamada, et al.
Anticancer Research|June 23, 2023
Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint InhibitorsMinehiko Inomata, Masahiro Matsumoto, Kana Hayashi, et al.
Molecular and Clinical Oncology|July 15, 2015
Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinibMinehiko Inomata, Ryuji Hayashi, Azusa Yamamoto, et al.
Scientific Reports|July 4, 2023
Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancerMinehiko Inomata, Masahiro Matsumoto, Naoki Takata, et al.
Arthritis Research & Therapy|November 26, 2016
Factors related to renal cortical atrophy development after glucocorticoid therapy in IgG4-related kidney disease: a retrospective multicenter studyIchiro Mizushima, Motohisa Yamamoto, Dai Inoue, et al.
Endocrine Journal|May 20, 2015
Association of serum adiponectin with asthma and pulmonary function in the Japanese populationYasuko Hayashikawa, Minoru Iwata, Minehiko Inomata, et al.
Molecular and Clinical Oncology|May 17, 2024
Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expressionMinehiko Inomata, Shuhei Minatoyama, Naoki Takata, et al.
Pageof 9